Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis

Paula RackoffDivision of Rheumatology, Beth Israel Medical Center, New York, NY, USAAbstract: Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, howev...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Paula Rackoff
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	risedronate postmenopausal osteoporosis Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/2e882e93e2ed4f66b1cbb41c040349be
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2e882e93e2ed4f66b1cbb41c040349be
record_format	dspace
spelling	oai:doaj.org-article:2e882e93e2ed4f66b1cbb41c040349be2021-12-02T00:02:42ZEfficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis1178-1998https://doaj.org/article/2e882e93e2ed4f66b1cbb41c040349be2009-05-01T00:00:00Zhttps://www.dovepress.com/efficacy-and-safety-of-risedronate-150-mg-once-a-month-in-the-treatmen-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Paula RackoffDivision of Rheumatology, Beth Israel Medical Center, New York, NY, USAAbstract: Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, however, is often less than optimal due to poor compliance with medications. Studies have demonstrated that risedronate, a heterocyclic nitrogen containing bisphosphonate can reduce vertebral, nonvertebral, and hip fracture incidence in postmenopausal women, in men, and in subsets of older patients at great risk of falls and fragility. The mechanism, efficacy, dosing options, and tolerability of risedronate are reviewed.Keywords: osteoporosis, fracturePaula RackoffDove Medical Pressarticlerisedronatepostmenopausal osteoporosisGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 4, Pp 207-213 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	risedronate postmenopausal osteoporosis Geriatrics RC952-954.6
spellingShingle	risedronate postmenopausal osteoporosis Geriatrics RC952-954.6 Paula Rackoff Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
description	Paula RackoffDivision of Rheumatology, Beth Israel Medical Center, New York, NY, USAAbstract: Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, however, is often less than optimal due to poor compliance with medications. Studies have demonstrated that risedronate, a heterocyclic nitrogen containing bisphosphonate can reduce vertebral, nonvertebral, and hip fracture incidence in postmenopausal women, in men, and in subsets of older patients at great risk of falls and fragility. The mechanism, efficacy, dosing options, and tolerability of risedronate are reviewed.Keywords: osteoporosis, fracture
format	article
author	Paula Rackoff
author_facet	Paula Rackoff
author_sort	Paula Rackoff
title	Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
title_short	Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
title_full	Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
title_fullStr	Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
title_full_unstemmed	Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
title_sort	efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/2e882e93e2ed4f66b1cbb41c040349be
work_keys_str_mv	AT paularackoff efficacyandsafetyofrisedronate150mgonceamonthinthetreatmentofpostmenopausalosteoporosis
_version_	1718403974901530624

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis

Ejemplares similares